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Introduction
Diabetes Mellitus type 2 (T2DM) is a 
common, etiologically complex chronic 
disorder that arises from the elaborate 
interplay between lifestyle factors and 
various genetic elements. It represents 
one of the most widespread public 
health problems in both the developed 
and developing world. Commonly, 
the impaired regulation of glucose 
homeostasis that leads to type 2 
diabetes is associated with a cluster of 
cardio-metabolic risk factors - including 
abdominal obesity, hypertension and 
atherogenic dyslipidaemia, which is a 
chronic subclinical proinflammatory state. 
These factors combine to determine 
the development and progression of 
both microvascular and macrovascular 
disease that carry a substantial socio-
economic burden globally. Central to 
the development of obesity, insulin 
resistance and type 2 diabetes is a 
distinct lifestyle component defined by 
the overconsumption of calorie-dense 
food and a lack of physical exercise. 
Background 
The study of complex disease genetics 
has undergone a massive revolution 
over the past decade, driven largely by 
the completion of the Human Genome 
and the International HapMap projects.1 
These have provided researchers with 
innovative insight into population-specific 
patterns of common human genetic 
variation. Simultaneously, technological 
advances have led to the development 
of DNA microarray platforms. These 
commercially available ‘DNA chips’ utilize 
known linkage disequilibrium patterns to 
genotype tag polymorphisms and enable 
the imputation of genotypes at linked 
loci. Ongoing developments in second-
generation sequencing technology have 
enabled the processing of millions of 
sequence reads in parallel. These have 
continued to drive down the cost and 
timeframes necessary to obtain whole 
genome and transcriptome datasets 
which are vital to understanding complex 
diseases. 
candidate Gene or Genome-Wide 
Association Studies?
The search for T2DM susceptibility loci 
has been fraught with complications. The 
disease is genetically heterogeneous, and 
strong gene-environment interactions 
influence its onset and progression. 
Furthermore, the diagnosis of T2DM 
hinges on the identification of elevated 
fasting or post-prandial blood glucose 
levels that lead to metabolic and 
microvascular complications. It is 
highly likely that such a diagnosis 
masks a tremendous amount of clinical 
heterogeneity, and that the genetic 
heterogeneity behind diabetes is as great 
as its clinical heterogeneity.2 Hypothesis-
driven candidate gene studies have 
identified a few genetic variants associated 
with T2DM. These include common 
variants in peroxisome proliferator-
activated receptor γ (PPARy),3 the KCNJ11 
potassium channel4 and the transcription 
factor TCF7L2.5 Such candidate gene 
studies are based on selection of loci with 
a known or inferred biological function 
which may predispose to disease or the 
observed phenotype.6 Nevertheless such 
a priori assumption inherently limits the 
capacity of candidate gene studies to 
identify pathways or loci playing previously 
unsuspected roles in the etiology or 
pathogenesis of complex diseases.
The genomics revolution and the 
subsequent introduction of Genome-Wide 
Association Studies (GWAS) in 2007 has 
lead to a massive upsurge in the number 
of T2DM-associated loci. To date, the 
online catalog of published Genome-Wide 
Association Studies (www.genome.gov/
gwastudies/) lists 43 GWAS that have 
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investigated T2DM as a disease of which 8 
GWAS have also investigated fasting blood 
glucose as a quantitative trait. As larger 
collections continue to be assembled for 
meta-analysis by international consortia, 
new associations with T2DM, fasting blood 
glucose and fasting insulin continually 
emerge.7
GWAS – a failed promise? 
Hundreds of variants identified through 
GWAS have been associated with complex 
traits or diseases, including T2DM. In 
some cases, the identified variants have 
provided valuable insight into the genetic 
architecture of disease. However, GWAS-
identified variants have a low effect size 
and consequently confer only slight 
increments in risk and account for a minor 
proportion of familial clustering.8 GWAS-
identified associations are estimated to 
explain only around 10% of the heritability 
of T2DM. They fail to account for epistasis, 
epigenetic changes and gene-environment 
interactions. They are largely restricted to 
populations of European descent and carry 
poor discriminatory capacity that limits 
their use in risk prediction. Furthermore, 
the transition from genotype to functional 
physiology is not straightforward. While 
polymorphisms in promoter or exon 
regions have predictable biological effects, 
variants in deep intronic or intergenic 
regions have probable regulatory roles. 
GWAS also utilise large cohorts of 
patients that are often heterogeneous or 
poorly characterised, thus limiting the 
association of genotype data with clinical 
or biochemical phenotypes. 
Type 2 Diabetes Genetics and the 
Maltese Population
The Maltese population has a high 
predisposition for T2DM. The earliest 
evidence concerning interest in diabetes 
in Malta dates back to 1698.9 The 
period following the Second World War 
witnessed an improvement in socio-
economic conditions which, despite the 
introduction of oral hypoglycemic agents, 
was accompanied by a marked increase in 
diabetes-specific mortality. The estimated 
national prevalence for T2DM in 2013 
stands at 10.14% and is expected to rise 
to 11.44% by 2035.10
SWEET REflEcTIONS
Abstract
The genomic revolution has transformed 
the type 2 diabetes genetic landscape, 
with many loci reported to have 
association with disease risk. Such 
loci exert a weak to modest effect size 
and are as yet of limited use in risk 
prediction studies. They also fail to 
account for robust genotype-phenotype 
associations. This study aims to 
address these issues by looking at the 
quantitative summation of risk alleles and 
the use of special populations to better 
define risk and phenotypic associations. 
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Two studies have investigated 
the genetics of T2DM in the Maltese 
population.11,12 The aims are listed 
hereunder. 
1. Further define the genetic interplay 
between a carefully selected panel 
of genes from metabolic and 
inflammatory pathways and the risk 
of developing type 2 diabetes in 
adulthood.
2. To relate the association of defined 
genetic profiles with biological and 
clinical endpoints and monocyte gene 
expression profiles to type 2 diabetes.
These studies were innovative in 
several key points. A total of 42 genetic 
variants were selected for genotyping 
from genes in several metabolic and/
or inflammatory pathways that impact 
on glucose regulation, lipid metabolism, 
inflammation and insulin resistance. The 
genetics of the disease was investigated 
using different comparative populations, 
including 600 Maltese and 200 Libyan 
T2DM cases. The Maltese T2DM cases 
were further subdivided into carefully 
defined subpopulations of treatment-naïve 
and high-morbidity groups. A unique 
collection of two hundred cord blood 
DNA samples obtained from the Malta 
BioBank (www.um.edu.mt/biobank/home) 
was selected as the control reference 
population. These were carefully selected 
to be of Maltese ethnicity and to exclude 
close siblings. 
The salient findings of these 
investigations are the following:
1. The quantitative summation of 
risk alleles has been associated 
with significant increases in the 
risk of developing T2DM (figure1).
Nevertheless, when individual cases 
are considered, risk polymorphisms 
exerted only a slight-to-modest effect 
on disease risk. Consequently, risk 
alleles studied in isolation contribute 
minimally to disease risk prediction. 
Equally interesting is the high odds 
ratios for selected risk alleles reported 
in these studies, in particular for 
a common variant in the beta-2 
adrenergic receptor (ADRβ2). 
2. The recruitment of a carefully-
characterised treatment-naïve cohort 
is a powerful tool in the identification 
of genotype-phenotype associations. 
The clinical, anthropometric and 
biochemical risk factors were, as 
much as possible and to our 
knowledge, unaltered by drugs 
and/or lifestyle change. Too often, 
published genotype-phenotype 
associations included larger 
numbers of less well-characterized 
subjects that were clinically 
heterogeneous. Such associations 
have doubtful pathophysiological 
relevance, lacked reproducibility or 
were replicated with disconcordant 
findings. Drugs commonly used in 
the management of T2DM, including 
metformin, statins and aspirin, exert 
their effects on multiple tissue types 
through various signaling pathways 
that could rapidly alter the systemic 
metabolic and inflammatory 
profile. Of note, the authors have 
identified an association between 
a promoter polymorphism in the 
melatonin-receptor 1 beta gene 
(MTNR1β) and total cholesterol and 
LDL-C levels which has also been 
reported in other ethnic groups.13 
Other significant genotype-
phenotype associations which have 
been identified include promoter 
polymorphism in Interleukin-6 with 
insulin resistance index (HOMA-
IR), and an insulin growth factor 1 
variant (IGF1) with body weight.
3. Despite the increased effort to 
recruit treatment-naïve subjects 
and the aforementioned findings, 
genotype-phenotype associations 
still remain considerably deficient. 
This strongly suggests that while 
genetic factors contribute to 
disease risk and onset, the end 
clinical phenotype is highly variable 
and is influenced by complex non-
genetic factors. 
4. Microarray gene expression analysis 
of peripheral blood leukocytes in 
T2DM provides an intriguing insight 
into their role in inflammation and 
the development and progression 
of diabetic complications. While 
there is no clear direct relationship 
between genetic risk scores 
and gene expression profiles, 
bioinformatic approaches have 
identified differentially expressed 
genes that have established roles in 
inflammation, oxidative damage and 
leukocyte activation.  
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figure 1.  Log10 risk ratio of T2DM in a study meta-analysis vs. increasing number of risk alleles.
An unweighted genetic score was constructed by the simple count of risk alleles. This method 
assumed that each allele exerts equal and additive effects that can be summed. Genetic risk 
scores identify a gradient of genetic risk in the T2DM population, with individuals at the high end 
of the genetic risk score distribution having a markedly higher individual risk than those at the 
lower end of the genetic risk score distribution. The predictive nature of genetic risk scores in 
this investigation is limited by the cross-sectional study design.
Acknowledgements
The research work disclosed in this article 
was funded by the Strategic Educational 
Pathways Scholarship Scheme – STEPS 
(Malta) and by institutional funds of the 
University of Malta. The STEPS scholarship 
is part-financed by the European Union 
– European Social Fund (ESF) under 
Operational Programme II- Cohesion Policy 
2007-2013, “Empowering people for More 
Jobs and a Better Quality of Life”
We acknowledge the invaluable contribution 
of all the staff and patients at the Diabetes 
and Endocrine Clinic, Mater Dei Hospital 
and to the family medicine practitioners 
who helped in the recruitment of the study 
cohorts for this project.
9
